BREAST STAGING DIAGRAM (For CLINICIAN USE)

| ☐ Right Breast | ☐Left Breast |
|----------------|--------------|
| ~ | |
| | |

Note:

- "Central area" as shown
 by solid circle around the
 areola is defined as a 3 cm. radius
 from edge of the nipple
- 2. Indicate scars on Staging Diagram
- 3. Tumour size guidelines:
 - stated size larger than 2.0 cm, record 2.1
 - stated size less than 2.0 cm, record 1.9
 - if recovered in more than 1 piece, take longest dimension of the larger piece & add to the shortest dimension of the smaller piece.
 - neoadj. cases: use mammogram or clinical size prior to definitive treatment
 - multifocal tumours: record dimension of largest tumour
 - DCIS with foci of microinvasion and no definite pathological dimension stated: record as 0.1 cm

| Anatomical Subsite: | | | | | | | |
|---|----------|-------------------|-----------------|-----------------------------|--|--|--|
| Pathological Diagnose | es: | | | | | | |
| ☐ Tumour palpable | _ | | | | | | |
| Size of breast tumour:cms | | | | | | | |
| STAGE: | | | | | | | |
| CLINICAL STAGE: | cT _ | cN | cM | (See next page for staging) | | | |
| PATHOLOGICAL STAGE: | рТ _ | pN | pM | (See next page for staging) | | | |
| | □ No | o primary surgery | (eg. locally ad | dvanced or metastatic) | | | |
| SYSTEMIC FA | CTORS | | LOCAL FACTORS | | | | |
| Nottingham Grade:/3 Estrogen Receptor:/3 Progesterone Receptor:/3 Her ₂ Amplification: IHC/3 FISH +veve Lymphatic Invasion: +veve unknown Venous Invasion: +veve unknown Neural Invasion: +veve unknown Pathological size: cms (If recovered in more than one piece, take longest dimension of the larger piece & add to the shortest dimension of smaller piece) | | | Final Margins: | | | | |
| Completed by: | | | Date: | | | | |
| Diagnosis/Stage amended to | o: | | | | | | |
| Reason: | | | | | | | |
| Ву: | By:Date: | | | | | | |
| NOTIFY PATIENT INFORMATION MANAGEMENT (PIM) IF STAGE/DIAGNOSIS IS AMENDED FORM #TH-63 Revised February/2003 (60063) | | | | | | | |

| | NICAL | TNM CLASSIFICATION (2002) | | THOLOGIC | SAL TNM CLASSIFICATION (2002) |
|--------|----------|---|-----|--------------|--|
| Т | | PRIMARY TUMOUR | pΝ | | REGIONAL LYMPH NODES |
| | TΧ | Primary tumour cannot be assessed | | pNX | Regional lymph nodes cannot be assessed |
| | T0 | No evidence of primary tumour | | pN0 | No regional lymph nodes metastasis histologically , no |
| | Tis | (DCIS) Ductal carcinoma insitu | | | additional examination for isolated tumour cells (ITC)*** |
| | Tis | (LCIS) Lobular carcinoma in situ | | pN0(i-) | No regional lymph node metastasis histologically, |
| | Tis | (Paget's) Paget's disease of the nipple with no tumour | | . , , | negative IHC |
| Note | | Paget's disease associated with a tumour is classified | | pN0(i+) | No regional lymph node metastasis histologically, |
| | | according to the size of the tumour | _ | p () | positive IHC, no IHC cluster greater than 0.2 mm |
| \Box | T1 | Tumour 2 cm or less in greatest dimension | | pN0(mol-) | No regional lymph node metastasis histologically, |
| | T1mic | Microinvasion 0.1 cm or less in greatest dimension | | prvo(mor) | negative molecular findings (RT-PCR) |
| _ | T1a | | | nNO(molu) | |
| _ | | > 0.1 cm but ≤ 0.5 cm in greatest dimension | | pN0(mol+) | No regional lymph node metastasis histologically, |
| = | T1b | > 0.5 cm but ≤ 1 cm in greatest dimension | | | positive molecular findings (RT-PCR) |
| _ | T1c | > 1 cm but ≤ 2 cm in greatest dimension | | Note: | RT-PCR: reverse transcriptase/polymerase chain |
| | Γ2 | > 2 cm but ≤ 5 cm in greatest dimension | | | reaction |
| | Т3 | > 5 cm in greatest dimension | | pN1 | Metastasis in 1 to 3 axillary lymph nodes, and/or in |
| | Τ4 | Tumour of any size with direct extension to chest | _ | • | internal mammary nodes with microscopic disease |
| _ | | wall/skin | | | detected by sentinel lymph node dissection, but not |
| | T4a | Extension to chest wall, not including pectoralis muscle | | | clinically apparent** |
| | T4b | Edema (including peau d'orange), or ulceration of the | | pN1mi | Micrometastasis (greater than 0.2 mm, none greater than |
| | 1 10 | skin of the breast, or satellite skin nodules confined to | | premi | 2.0 mm) |
| | | the same breast | | pN1a | Metastasis in 1 to 3 axillary lymph nodes |
| | T40 | | ᅵ뭐 | | |
| | T4c | Both 4a and 4b | | pN1b | Metastasis in internal mammary nodes with microscopic |
| | T4d | Inflammatory carcinoma | | | disease detected by sentinel lymph node dissection, but |
| N | | REGIONAL LYMPH NODES | I | | not clinically apparent ** |
| | NX | Regional lymph nodes cannot be assessed | | pN1c | Metastasis in 1 to 3 axillary lymph nodes and in internal |
| | N0 | No regional lymph nodes metastasis | Ī | | mammary nodes, with microscopic disease detected by |
| | N1 | Metastasis to movable ipsilateral axillary node(s) | | | sentinel lymph node dissection, but not clinically |
| | N2 | Metastasis to ipsilateral axillary lymph nodes fixed or | | | apparent** (if associated with more than 3 positive |
| | | matted, or in <i>clinically apparent*</i> ipsilateral internal | | | axillary lymph nodes, the internal mammary nodes are |
| | | mammary nodes in the <i>absence</i> of clinically evident | | | classified as pN3b to reflect in increased tumour burden.) |
| | | axillary lymph nodes metastasis | | pN2 | Metastasis in 4 to 9 axillary lymph nodes, or in <i>clinically</i> |
| | N2a | Metastasis in ipsilateral axillary lymph nodes fixed to | | p | apparent* internal mammary lymph nodes in the |
| | | one another (matted) or to other structures. | | | absence of axillary lymph nodes metastasis |
| | N2b | Metastasis only in <i>clinically apparent*</i> ipsilateral internal | | pN2a | Metastasis in 4 to 9 axillary lymph nodes (at least 1 |
| ш | INZU | | | pivza | |
| | | mammary nodes in the <i>absence</i> of clinically evident | | nNOh | tumour deposit greater than 2.0 mm) |
| | NO | axillary lymph node metastasis | | pN2b | Metastasis in <i>clinically apparent*</i> internal mammary |
| | N3 | Metastasis in ipsilateral infraclavicular lymph node(s), | | | lymph nodes in the absence of axillary lymph nodes |
| | | with or without axillary lymph node involvement, or in | _ | NO | metastasis |
| | | clinically apparent* ipsilateral internal mammary lymph | | pN3 | Metastasis in 10 or more axillary lymph nodes, or in |
| | | nodes in the <i>presence</i> of clinically evident axillary lymph | | | infraclavicular lymph nodes, or in <i>clinically apparent*</i> |
| | | node metastasis; or metastasis in ipsilateral | | | ipsilateral internal mammary lymph nodes in the |
| | | supraclavicular lymph node(s), with or without axillary or | | | present of 1 or more positive axillary lymph nodes; or in |
| | | internal mammary lymph node involvement | | | more than 3 axillary lymph nodes with clinically negative |
| | N3a | Metastasis in ipsilateral infraclavicular lymph node(s) | | | microscopic metastasis in internal mammary lymph |
| | | and axillary lymph node | | | |
| | N3b | Metastasis in ipsilateral internal mammary lymph | | | nodes; or in ipsilateral supraclavicular lymph nodes |
| | | node(s) and axillary lymph node(s) | | pN3a | Metastasis in 10 or more axillary lymph nodes (at least 1 |
| | N3c | Metastasis in ipsilateral supraclavicular lymph node(s) | | | tumour deposit greater than 2.0 mm), or metastasis to |
| M | | DISTANT METASTASIS | | | the infraclavicular lymph nodes |
| | MX | Presence of distant metastasis cannot be assessed | | pN3b | Metastasis in <i>clinically apparent*</i> ipsilateral internal |
| | MO | No distant metastasis | _ | p. 102 | mammary lymph nodes in the presence of 1 or more |
| Ħ | M1 | Distant metastasis | | | positive axillary lymph nodes; or in more than 3 axillary |
| | 141 1 | Distant metastasis | | | lymph nodes and in internal mammary lymph nodes with |
| | | | | | • • • |
| | TI 10: - | ACICAL THIS OF ACCIDIOATION (COCC) | | | microscopic disease detected by sentinel lymph node |
| PA | HOLC | OGICAL TNM CLASSIFICATION (2002) | l | | dissection, but not clinically apparent** |
| | | | Ш | pN3c | Metastasis in ipsilateral supraclavicular lymph nodes |
| рТ | | PRIMARY TUMOUR | M | | DISTANT METASTASIS |
| | TX | Primary tumour cannot be assessed | | pMX | Presence of distant metastasis cannot be assessed |
| | T0 | No evidence of primary tumour | | pM0 | No distant metastasis |
| | T1 | Tumour 2 cm or less in greatest dimension | | pM1 | Distant metastasis |
| | Tis | (DCIS) Ductal carcinoma insitu | 1 | - | |
| Ħ | Tis | (LCIS) Lobular carcinoma in situ | NOT | E: | |
| \Box | Tis | Paget's disease of the nipple with no tumour | mic | | ion is the extension of cancer cells beyond the basement |
| | T1mic | Microinvasion 0.1 cm or less in greatest dimension | 0 | | into the adjacent tissues with no focus more than 0.1cm in |
| Ħ | T1a | _ | | | mensions. When there are multiple foci of microinvasion, |
| | T1b | > 0.1 cm but ≤ 0.5 cm in greatest dimension | | | only the largest focus is used to classify the microinvasion. |
| 님 | | > 0.5 cm but ≤ 1 cm in greatest dimension | | | |
| | T1c | > 1 cm but ≤ 2 cm in greatest dimension | | | e the sum of all the individual foci) The presence of |
| _ | _ | | | multiple | |
| | pT2 | > 2 cm but ≤ 5 cm in greatest dimension | | foci of micr | oinvasion should be noted, as it is with multiple larger |
| | pT3 | > 5 cm in greatest dimension | | invasive ca | arcinomas |
| | pT4 | Tumour of any size with direct extension to chest | * | Clinically a | pparent is defined as detected by imaging studies |
| | - | wall/skin | | | lymphoscintigraphy) or by clinical examination |
| | pT4a | Extension to chest wall, not including pectoralis | ** | | lly apparent is defined as not detected by imaging studies |
| _ | | muscle | | | lymphoscintigraphy) or by clinical examination |
| | pT4b | Edema (including peau d'orange), or ulceration of the | *** | | mour cells (ITC) are defined as single tumour cells or small |
| | F . 10 | skin of the breast, or satellite skin nodules confined to | | | s not greater than 0.2 mm, usually detected only by |
| | | the same breast | | immunohie | tochemical (IHC) or molecular methods, but which may be |
| | pT4c | Both 4a and 4b | | | H&E stains. ITCs do not usually show evidence of |
| H | pT4d | Inflammatory carcinoma | | | activity (eg. proliferation or stromal reaction) |
| ш | P I Tu | illiaminatory outofforma | I | mangnant | activity (og. promoration of stronial reaction) |